Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has…
NCT00005992 · Jonsson Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00005992 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | Phase I Clinical Trial of Recombinant Prostate Specific Membrane Antigen (rPSMA)-Loaded Mature Autologous Dendritic Cells (CapPVax) for the Treatment of Metastatic Horomone Refractory Prostate Cancer |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | PSA prostate cancer vaccine, therapeutic autologous dendritic cells |
| Start date | Dec 1, 2000 |
| First posted | Mar 24, 2004 |
| Last update posted | Aug 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: